As drug makers around the world continue to navigate the complex and ever-changing landscape referred to as the New Health, many companies are flocking to Asia-Pacific for better access to patients, improved operational efficiencies and increasingly, pharmaceutical innovation.
In a new report released today, Ferzaan Engineer, Ph.D., Chief Executive Officer of Quintiles India and Anand Tharmaratnam, M.D., Senior Vice President and Head of Clinical Development for Quintiles Asia-Pacific, provide an in-depth analysis of the Asia-Pacific drug development landscape and its evolution from outsourcing destination to potential pharmaceutical innovation hub of the future.
The report, “Realizing the Promise of Asia-Pacific,” explores the history, growth and opportunities of the Asia-Pacific region as part of the larger biopharmaceutical drug development industry. Drs. Engineer and Tharmaratnam examine the region’s ongoing transformation and explore some of the key initiatives, characteristics and advantages that they believe will be integral to the overall success of the region in the New Health landscape.
In addition, Engineer and Tharmaratnam provide their perspective on what countries in this emerging region must do in order to realize the full extent of their potential. From advancements in intellectual property protection (IPP), to harmonization of regulatory guidelines to education and disease focus, this report provides unique perspective from two regional industry leaders on the front lines of drug development in Asia-Pacific.
The full report is available for download at www.quintiles.com/perspectives/.
Dr. Tharmaratnam will be providing additional insight on many of the topics outlined in this paper during his keynote presentation at the World Pharma Trials Asia 2010 conference taking place this week at Raffles City Convention Centre in Singapore. Tharmaratnam’s presentation will begin at 9:05 a.m. on Thursday, March 18.